BLUEROCK THERAPEUTICS
Live / Applied — Statement of use — registration review complete (as of 08 Sept 2026)
What this means for you
Not registered yet, but its 25 Jul 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97981627
- Mark type
- Design + words
- Filed
- 25 Jul 2022
- Published for opposition
- 19 Sept 2023
- Attorney of record
- Phillip Barengolts
Goods and services
- Class 042 — Scientific and technological services: Medical and scientific research services in the fields of gene therapy and cell therapy; pharmaceutical research and development services; biochemical or pharmaceutical laboratory services, namely, cultivation and purification of cells, namely, of body cells and cells of the immune system of mammals including human cells
Owner
- BlueRock Therapeutics LP, Cambridge, MA, US
- BlueRock Therapeutics LP, Cambridge, MA, US
Prior registrations
Prosecution history
- 08 Sept 2026 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 08 Sept 2026 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 17 Aug 2026 — STATEMENT OF USE PROCESSING COMPLETE
- 21 Apr 2026 — USE AMENDMENT FILED
- 17 Aug 2026 — DIVISIONAL PROCESSING COMPLETE
- 21 Apr 2026 — DIVISIONAL REQUEST RECEIVED
- 14 Aug 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 21 Apr 2026 — TEAS REQUEST TO DIVIDE RECEIVED
- 21 Apr 2026 — TEAS STATEMENT OF USE RECEIVED
- 05 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 04 Nov 2025 — SOU EXTENSION 4 GRANTED
- 04 Nov 2025 — SOU EXTENSION 4 FILED
- 04 Nov 2025 — SOU TEAS EXTENSION RECEIVED
- 06 May 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 06 May 2025 — SOU EXTENSION 3 GRANTED